BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of XBiotech, Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT) concerning the Company’s and its officers’ possible violations of federal securities laws. Howard G. Smith, Esq. is preparing a lawsuit on behalf of injured XBiotech investors.
On November 23, 2015, XBiotech issued a press release announcing that data related to one of its Phase III studies was compromised due to fewer numbers of per protocol patients available for primary endpoint evaluation. The Company found that: (1) 25 patients dropped out of the study before receiving any dosing with drug or placebo; (2) 14 patients incorrectly received either placebo or study drug; and, (3) 33 patients finished the study but failed to receive scheduled DEXA scans, properly complete EORTC evaluation, or both. In total, the combined irregularities compromised data from 72 patients in the study.
On this news, XBiotech shares fell more than 30% during intra-day trading on November 24, 2015, thereby injuring investors.
If you purchased XBiotech securities and have suffered a loss, or if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, toll-free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.